View Older Stories View More Recent Stories

Oct 25, 2022 08:00AM Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences
Oct 21, 2022 07:00AM Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
Oct 20, 2022 07:59AM Lantern Pharma (LTRN) Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
Oct 20, 2022 07:59AM Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
Oct 11, 2022 04:00PM Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
Oct 5, 2022 08:00AM Lantern Pharma to Present at Upcoming Investor Conferences
Sep 23, 2022 08:52AM Lantern Pharma (LTRN) to Present Positive Preclinical Data on the Efficacy of LP-284
Sep 23, 2022 08:50AM Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
Sep 19, 2022 08:50AM Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
Sep 14, 2022 08:50AM Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
Aug 30, 2022 09:00AM Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022
Aug 19, 2022 08:30AM Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Aug 8, 2022 04:01PM Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
Aug 1, 2022 07:00AM Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
Jul 14, 2022 07:00AM Lantern Pharma (LTRN) Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
Jul 14, 2022 07:00AM Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
May 12, 2022 07:00AM Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month
May 5, 2022 07:00AM Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
May 3, 2022 04:01PM Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights
Apr 26, 2022 07:17AM Lantern Pharma (LTRN) Appoints Maria Maccecchini to its Board
Apr 26, 2022 07:15AM Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors
Apr 22, 2022 07:00AM Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET
Mar 22, 2022 07:00AM Lantern Pharma (LTRN) Announces Extension of Existing Share Repurchase Program
Mar 22, 2022 07:00AM Lantern Pharma Announces Extension of Existing Share Repurchase Program
Mar 14, 2022 07:00AM Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
Mar 10, 2022 04:05PM Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights
Mar 3, 2022 07:00AM Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Feb 15, 2022 06:59AM Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio
Jan 24, 2022 07:02AM Lantern Pharma (LTRN) Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor
Jan 24, 2022 07:00AM Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of
Jan 18, 2022 06:32AM Lantern Pharma (LTRN) Enters Collaboration & Research Agreement with The Danish Cancer Society Research Center for Development of LP-100 and LP-184, in Solid Tumors
Jan 18, 2022 06:30AM Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Jan 12, 2022 06:05AM Lantern Pharma (LTRN) Expands Oncology Collaboration with the National Cancer Institute
Jan 12, 2022 06:03AM Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284
Jan 4, 2022 09:29AM Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference
Dec 14, 2021 09:02AM Lantern Pharma (LTRN) Reports Positive Efficacy Data of LP-284 in Hematologic Cancers
Dec 14, 2021 09:01AM Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 22, 2021 09:01AM Lantern Pharma (LTRN) Announces $7M Share Buyback
Nov 22, 2021 09:00AM Lantern Pharma Announces Share Repurchase Program
Nov 12, 2021 09:40AM Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day
Nov 11, 2021 09:15AM Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting
Nov 9, 2021 09:00AM Lantern Pharma to Participate in Two Upcoming Investor Conferences
Nov 4, 2021 09:37AM Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Nov 1, 2021 04:05PM Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights
Nov 1, 2021 09:15AM Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Po
Oct 27, 2021 09:05AM Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations
Oct 27, 2021 08:02AM Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development
Oct 25, 2021 04:57PM Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET
Sep 30, 2021 09:00AM Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
Sep 28, 2021 09:20AM Lantern Pharma (LTRN) Enters into Strategic Collaboration with Deep Lens
View More Recent Stories View Older Stories